British Journal of Diabetes最新文献_第3页

Abstracts from ABCD Diabetes Update Diabetes Update糖尿病更新摘要

IF 0.6

British Journal of Diabetes Pub Date : 2023-06-28 DOI: 10.15277/bjd.2023.406

Diabetes Update 2023

引用次数: 1

Pembrolizumab and diabetes: a case of diabetic ketoacidosis in a patient with metastatic melanoma Pembrolizumab与糖尿病：一例转移性黑色素瘤患者的糖尿病酮症酸中毒

IF 0.6

British Journal of Diabetes Pub Date : 2023-06-28 DOI: 10.15277/bjd.2023.410

Songo Lolomari, S. Thayyil, M. Kong

{"title":"Pembrolizumab and diabetes: a case of diabetic ketoacidosis in a patient with metastatic melanoma","authors":"Songo Lolomari, S. Thayyil, M. Kong","doi":"10.15277/bjd.2023.410","DOIUrl":"https://doi.org/10.15277/bjd.2023.410","url":null,"abstract":"Introduction The advent of immunotherapy has revolutionised the management of certain malignancies, and its use has increased over the past decade. Monoclonal antibody therapies known as checkpoint inhibitors work by enhancing the immune response against malignant cells by blocking the pathways that inhibit T-cell regulation. Checkpoint inhibitors can be administered alone or in combination as an intravenous infusion every 3-6 weeks for a maximum of two years. However, about 10% of patients may experience endocrine adverse effects. Thyroid disease and hypophysitis are those most commonly encountered; there are also reports of diabetes mellitus and primary adrenal insufficiency as well as rarer endocrinopathies. Pembrolizumab, an immune checkpoint inhibitor, received FDA approval in 2014 for advanced melanoma, and in 2015 for metastatic non-small cell lung cancer. It is also approved for recurrent/metastatic head and neck cancer, and for refractory classical Hodgkin’s lymphoma. We report the case of a 75-year-old man who developed new-onset diabetes mellitus and diabetic ketoacidosis while undergoing pembrolizumab chemotherapy for metastatic melanoma. He was not taking steroids.","PeriodicalId":42951,"journal":{"name":"British Journal of Diabetes","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2023-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43141030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effective analysis of using total contact casting for diabetic foot ulcer management 全接触铸造治疗糖尿病足溃疡的成本效益分析

IF 0.6

British Journal of Diabetes Pub Date : 2023-05-19 DOI: 10.15277/bjd.2023.404

Abbas See, Manjula Mallikage, Jacqueline Mildred, Andrea Friel, Mary Gray, S. Kirmani, M. Pierides

引用次数: 0

Diabetes mellitus and periodontal disease: education, collaboration and information sharing between doctors, dentists and patients 糖尿病和牙周病:医生、牙医和患者之间的教育、合作和信息共享

IF 0.6

British Journal of Diabetes Pub Date : 2023-04-28 DOI: 10.15277/bjd.2023.403

Chris Turner, P. Bouloux

{"title":"Diabetes mellitus and periodontal disease: education, collaboration and information sharing between doctors, dentists and patients","authors":"Chris Turner, P. Bouloux","doi":"10.15277/bjd.2023.403","DOIUrl":"https://doi.org/10.15277/bjd.2023.403","url":null,"abstract":"People living with diabetes (DM) are at higher risk of developing periodontal disease than those without diabetes. This observation was ﬁrst recorded in 1928. It is now believed that the risk is 3-4 times greater than for people without DM, and more for smokers. However, many doctors are not aware of this.\u0000DM and periodontal disease are bi-directionally linked, the one affecting the other and vice versa, although the mechanism is not fully understood. Periodontal disease has an adverse effect on glycaemic control. That improves when periodontitis is successfully treated.\u0000Doctors should consider periodontal disease when their patients have persistently high glycated haemoglobin (HbA1c) levels, and dentists should consider diabetes or pre-diabetes when they have patients with unstable periodontitis.\u0000Doctors and dentists, and their teams, need to share results. This paper considers what that shared information should be. A system of red, amber and green for both medical and dental risks is proposed. Until there are reliable methods of information exchanges and a paradigm shift in inter-professional working, patients should obtain their medical and dental results and share them with their respective advisors.\u0000Those patients who do not attend for dental care should be advised by their doctor about the potential beneﬁts of dental screening for periodontitis.","PeriodicalId":42951,"journal":{"name":"British Journal of Diabetes","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2023-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44821513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CRY1 polymorphism may inﬂuence the association of low carbohydrate diet (LCD) score on glucose homeostasis in overweight and obese women CRY1多态性可能影响超重和肥胖女性低碳水化合物饮食(LCD)评分与葡萄糖稳态的关联

IF 0.6

British Journal of Diabetes Pub Date : 2023-03-30 DOI: 10.15277/bjd.2023.402

A. Mirzababaei, Farideh Shiraseb, Sara Hajishizari, Mena Farazi, Hadith Tangestani, Leila Khorraminezhad, C. Clark, K. Mirzaei

{"title":"CRY1 polymorphism may inﬂuence the association of low carbohydrate diet (LCD) score on glucose homeostasis in overweight and obese women","authors":"A. Mirzababaei, Farideh Shiraseb, Sara Hajishizari, Mena Farazi, Hadith Tangestani, Leila Khorraminezhad, C. Clark, K. Mirzaei","doi":"10.15277/bjd.2023.402","DOIUrl":"https://doi.org/10.15277/bjd.2023.402","url":null,"abstract":"Background and aims: We sought to examine the interaction between CRY1 genotypes and low carbohydrate diet (LCD) score and the effect on insulin resistance, insulin sensitivity, homeostasis model assessment of insulin resistance (HOMA- IR) and quantitative insulin sensitivity check index (ISQUKI).\u0000Methods: This cross-sectional study was conducted with a total of 228 overweight and obese women. The data related to anthropometric and biochemical measures were collected and a food frequency questionnaire (FFQ), with 147 items, was used to assess dietary intake. Based on the FFQ, we calculated an LCD score for each study participant, ranging from 0 to 70. Biochemical assessments, including TC, HDL, LDL, TG, FBS, insulin and HOMA-IR, were performed. Deoxyribonucleic acid (DNA) samples were assessed to be genotyped for the rs2287161, which was genotyped by the restriction fragment length polymorphism (PCR-RFLP) method. A generalised linear model was performed for interaction analysis.\u0000Results: The results of the study demonstrated that, after controlling for several confounders, increased adherence to an LCD (T3 vs. T1) in the interaction with one risk allele genotype (CG) increases ISQUKI level (β: 0.001, CI: 0.00, 0.002, p=0.041). Also, there was a marginally negative interaction between higher adherence to LCD and two risk alleles genotype (CC) on insulin level (β: -0.012, CI: 0-0.024, 0.001, p=0.054).\u0000Conclusions: This study revealed a negative interaction of CRY1 genotypes with two risk allele and higher LCD adherence on insulin level, and a positive interaction on ISQUKI. However, the mechanism of interaction between LCDs and CRY1 genotypes remains unclear.","PeriodicalId":42951,"journal":{"name":"British Journal of Diabetes","volume":"1 1","pages":""},"PeriodicalIF":0.6,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41731475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

British Journal of Diabetes (and Vascular Disease): a brief history 英国糖尿病(及血管疾病)杂志:简史

IF 0.6

British Journal of Diabetes Pub Date : 2022-12-22 DOI: 10.15277/bjd.2022.365

C. Day, Cliff Bailey

引用次数: 0

#We don't have to wait any more Closed-loop systems: transforming the landscape 我们不需要再等待任何闭环系统:改变景观

IF 0.6

British Journal of Diabetes Pub Date : 2022-12-22 DOI: 10.15277/bjd.2022.374

C. Boughton, R. Hovorka

引用次数: 0

100 years of insulin; 50 years of diabetic life* 胰岛素100年；糖尿病患者50年的生活*

IF 0.6

British Journal of Diabetes Pub Date : 2022-12-22 DOI: 10.15277/bjd.2022.379

Maggie Loughran

引用次数: 0

Gazing into the future. The next 100 years: the Medtronic perspective 展望未来。下一个100年:美敦力的视角

IF 0.6

British Journal of Diabetes Pub Date : 2022-12-22 DOI: 10.15277/bjd.2022.376

D. Turner

{"title":"Gazing into the future. The next 100 years: the Medtronic perspective","authors":"D. Turner","doi":"10.15277/bjd.2022.376","DOIUrl":"https://doi.org/10.15277/bjd.2022.376","url":null,"abstract":"While it is difficult to predict the next 100 years of development, the current Medtronic product innovation pipeline is changing the lives of people with diabetes. The MiniMedTM 780G system with GuardianTM 4 sensor and extended wear infusion set is the advanced hybrid closed-loop pump system currently available in the UK from Medtronic. It has been clinically proven to achieve >70% time in range and to lower HbA1c levels in people with diabetes. Medtronic continues to innovate in the hybrid closed-loop and insulin pump and sensor area. The company is developing new sensor technology and personalised closed-loop options for future patients. Medtronic recognises that not all people with diabetes will want to use an insulin pump and therefore is launching a Smart MDI system for people looking for more from MDI therapy. The Smart MDI system brings together a collection of tools that provides real-time insights and comprehensive reports. These make it easier for people with diabetes to manage life on multiple daily injections. The system combines predictive glucose management with the GuardianTM 4 sensor, with no finger pricks and personalised high and low alerts up to 60 minutes in advance. Personalised insulin management with the inpen device allows informed insulin dosing with integrated real-time glucose data trends and shareable insight reports. The Medtronic extended-wear infusion set is due to launch in the UK soon. It is focused on improving user experience. It is the only infusion set approved for longer wear (with a wear twice as long as standard infusion sets) without compromising comfort, safety or insulin delivery. This new set will also reduce traditional infusion set plastic waste by half.","PeriodicalId":42951,"journal":{"name":"British Journal of Diabetes","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43976330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Islet cell transplantation 胰岛细胞移植

IF 0.6

British Journal of Diabetes Pub Date : 2022-12-22 DOI: 10.15277/bjd.2022.364

Y. Cheah

引用次数: 0